摘要
目的:通过对ChiariⅠ畸形合并脊髓空洞症手术治疗临床路径与DRGs(Diagnosis Related Groups)成本控制绩效分析,评价单病种临床路径和DRGs医疗成本控制应用于临床管理的效果。方法:收集整理2005年10月至2006年9月脊髓空洞症科ChiariⅠ畸形合并脊髓空洞症手术治疗患者的信息,以其手术并发症发生率、平均住院天数、平均住院费用、患者满意率等作为评价指标,将实验组(应用临床路径和DRGs成本控制组)和对照组(未应用临床路径和DRGs成本控制组)进行对比分析。结果:应用临床路径和DRGs成本控制的患者与未应用这一方式的患者之间在手术并发症发生率、平均住院时间、平均住院费用、患者满意率方面有统计学显著差异。结论:单病种临床路径和DRGs成本控制模式应用于ChiariⅠ畸形合并脊髓空洞症手术治疗,可以明显促进CQI(Continuous Quality Improvement)、缩短平均住院时间,降低住院费用,提高患者满意率。
Objective:To evaluate the implementation effect of clinical pathway (CP) and DRGs cost control (CC) of surgical therapies for Chiari Ⅰ malformation complicated with syringomyelia patients. Methods:After consulting the information of the hospitalized patients after the surgical therapies from October 2005 to September 2006, we analyzed the effect of CP and CC using the average length of stay and the hospital charges for the patients as the evaluating indexes. Results:There was significant difference in CQI, the average length of stay, the hospital charges for the patients, and patient satisfaction between the CP-CC groups and the traditional groups. Conclusion: The method of clinical pathway and cost control can markedly improve medical quality and patient satisfaction, decrease the average length of stay and the hospital charges for surgical therapies for Chiari Ⅰ malformation complicated with syringomyelia patients.
出处
《中国医院》
2007年第4期27-30,共4页
Chinese Hospitals